Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:876153.
doi: 10.1155/2012/876153. Epub 2011 Dec 29.

Comparison of the Genetic Organization, Expression Strategies and Oncogenic Potential of HTLV-1 and HTLV-2

Francesca Rende  1 , Ilaria Cavallari, Maria Grazia Romanelli, Erica Diani, Umberto Bertazzoni, Vincenzo Ciminale
Affiliations

Comparison of the Genetic Organization, Expression Strategies and Oncogenic Potential of HTLV-1 and HTLV-2

Francesca Rende et al. Leuk Res Treatment. 2012.

Abstract

Human T cell leukemia virus types 1 and 2 (HTLV-1 and HTLV-2) are genetically related complex retroviruses that are capable of immortalizing human T-cells in vitro and establish life-long persistent infections in vivo. In spite of these apparent similarities, HTLV-1 and HTLV-2 exhibit a significantly different pathogenic potential. HTLV-1 is recognized as the causative agent of adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM). In contrast, HTLV-2 has not been causally linked to human malignancy, although it may increase the risk of developing inflammatory neuropathies and infectious diseases. The present paper is focused on the studies aimed at defining the viral genetic determinants of the pathobiology of HTLV-1 and HTLV-2 through a comparison of the expression strategies and functional properties of the different gene products of the two viruses.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison of the organization, alternative splicing, and coding potential of HTLV-1 and HTLV-2 mRNAs. Exon composition and coding potential of HTLV-1 and HTLV-2 alternatively spliced mRNAs. ORFs are indicated by colored boxes. Splice sites are indicated by numbers. n.d.: not determined.
Figure 2
Figure 2
Schematic representation of Tax-1 and Tax-2 structural and functional domains. The positions of the amino acids modified by ubiquitination, sumoylation, acetylation, and phosphorylation are indicated.
Figure 3
Figure 3
Comparison of the protein isoforms coded by the x-III ORF of HTLV-1 and HTLV-2. Indicated is the exon composition of the mRNAs (left) and the domain structure of the corresponding proteins (right) coded by the x-III ORFs of HTLV-1 and HTLV-2. HTLV-1 produces a single truncated x-III ORF: p21rex; HTLV-2 produces a family of truncated x-III isoforms ranging from 22 to 17 kDa. RBD/NLS: rna binding domain/nuclear localization signal; MD: multimerization domain; AD/NES: activation domain/nuclear export signal; PS: phosphorylation site.
Figure 4
Figure 4
Comparison of the cis acting regulatory elements of HTLV-1 and HTLV-2. Position of the cis acting posttranscriptional regulatory elements of HTLV-1 and HTLV-2 are indicated. RXRE: Rex-responsive element; CRS: cis-acting repressive sequences; CSE: cis-acting stimulatory element; CIE: cis acting inhibitory elements.
See this image and copyright information in PMC

References

    1. Lairmore M, Franchini G. Human T-cell leukemia virus types 1 and 2. In: Knipe DM, Howley PM, editors. Fields Virology. 5th edition. Vol. 2. Philadelphia, Pa, USA: Lippincott Williams & Wilkins; 2007. pp. 2071–2106.
    1. Felber BK, Paskalis H, Kleinman-Ewing C. The pX protein of HTLV-I is a transcriptional activator of its long terminal repeats. Science. 1985;229(4714):675–679. - PubMed
    1. Ciminale V, D’Agostino DM, Zotti L, Franchini G, Felber BK, Chieco- Bianchi L. Expression and characterization of proteins produced by mRNAs spliced into the X region of the human T-cell leukemia/lymphotropic virus type II. Virology. 1995;209(2):445–456. - PubMed
    1. Biswas HH, Kaidarova Z, Garratty G, et al. Increased all-cause and cancer mortality in HTLV-II infection. Journal of Acquired Immune Deficiency Syndromes. 2010;54(3):290–296. - PMC - PubMed
    1. Feuer G, Green PL. Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2. Oncogene. 2005;24(39):5996–6004. - PMC - PubMed

LinkOut - more resources